OpenAI acquires Orchestra Bio to boost AI‑driven drug research
AI-generated summary OpenAI announced the acquisition of Orchestra Bio to incorporate its AI tools and team into the life-sciences division. OpenAI has not released financial terms or detailed the exact roadmap for product integration with the Rosalind platform.